202 related articles for article (PubMed ID: 34964156)
1. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
Alkabbani W; Gamble JM
Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
[TBL] [Abstract][Full Text] [Related]
2. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
4. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
[TBL] [Abstract][Full Text] [Related]
5. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
[No Abstract] [Full Text] [Related]
6. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors.
Fadini GP; Bonora BM; Mayur S; Rigato M; Avogaro A
Diabetes Obes Metab; 2018 Mar; 20(3):740-744. PubMed ID: 29053207
[TBL] [Abstract][Full Text] [Related]
7. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Bonora BM; Raschi E; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
[TBL] [Abstract][Full Text] [Related]
8. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
9. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis.
Gravel CA; Krewski D; Mattison DR; Momoli F; Douros A
Br J Clin Pharmacol; 2023 Aug; 89(8):2430-2445. PubMed ID: 36912450
[TBL] [Abstract][Full Text] [Related]
10. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems.
Raschi E; Poluzzi E; Salvo F; Pariente A; De Ponti F; Marchesini G; Moretti U
Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):533-542. PubMed ID: 29625780
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
13. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
14. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
[TBL] [Abstract][Full Text] [Related]
15. Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Rigato M; Fadini GP; Avogaro A
Diabetes Obes Metab; 2023 Oct; 25(10):2963-2969. PubMed ID: 37402697
[TBL] [Abstract][Full Text] [Related]
16. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Colacci M; Fralick J; Odutayo A; Fralick M
Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
[TBL] [Abstract][Full Text] [Related]
18. Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
Rebordosa C; Thomsen RW; Tave AK; Madsen M; Beachler DC; Martinez D; Garcia-Esteban R; Plana E; Tormos A; Farsani SF; Perez-Gutthann S; Pladevall-Vila M
Diabetes Obes Metab; 2024 Apr; 26(4):1291-1304. PubMed ID: 38234181
[TBL] [Abstract][Full Text] [Related]
19. Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database.
Katsuhara Y; Ogawa T
Clin Drug Investig; 2020 Jul; 40(7):645-652. PubMed ID: 32451843
[TBL] [Abstract][Full Text] [Related]
20. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
